Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00264134|
Recruitment Status : Terminated
First Posted : December 12, 2005
Last Update Posted : January 20, 2010
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer Extensive Stage Unresectable||Drug: Docetaxel Drug: Irinotecan Drug: Carboplatin||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma|
|Study Start Date :||June 2003|
|Study Completion Date :||October 2005|
- Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
- Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00264134
|United States, Kentucky|
|Kentuckiana Cancer Institute|
|Louisville, Kentucky, United States, 40202|
|Principal Investigator:||Shawn Glisson, MD||Kentuckiana Cancer Institute|